25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Infant Bacterial Therapeutics AB (publ)
Buy, Hold or Sell?

Let's analyze Infant Bacterial Therapeutics AB (publ) together

I guess you are interested in Infant Bacterial Therapeutics AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Infant Bacterial Therapeutics AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Infant Bacterial Therapeutics AB (publ)

I send you an email if I find something interesting about Infant Bacterial Therapeutics AB (publ).

1. Quick Overview

1.1. Quick analysis of Infant Bacterial Therapeutics AB (publ) (30 sec.)










1.2. What can you expect buying and holding a share of Infant Bacterial Therapeutics AB (publ)? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr12.64
Expected worth in 1 year
kr2.63
How sure are you?
23.7%

+ What do you gain per year?

Total Gains per Share
kr-10.01
Return On Investment
-28.6%

For what price can you sell your share?

Current Price per Share
kr35.00
Expected price per share
kr34.00 - kr42.20
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Infant Bacterial Therapeutics AB (publ) (5 min.)




Live pricePrice per Share (EOD)
kr35.00
Intrinsic Value Per Share
kr-55.39 - kr-63.33
Total Value Per Share
kr-42.76 - kr-50.70

2.2. Growth of Infant Bacterial Therapeutics AB (publ) (5 min.)




Is Infant Bacterial Therapeutics AB (publ) growing?

Current yearPrevious yearGrowGrow %
How rich?$16.7m$30.4m-$8.6m-39.7%

How much money is Infant Bacterial Therapeutics AB (publ) making?

Current yearPrevious yearGrowGrow %
Making money-$3.3m-$3m-$339.7k-10.1%
Net Profit Margin-139,075.0%-55,273.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Infant Bacterial Therapeutics AB (publ) (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#552 / 917

Most Revenue
#744 / 917

Most Profit
#345 / 917

Most Efficient
#907 / 917
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Infant Bacterial Therapeutics AB (publ)?

Welcome investor! Infant Bacterial Therapeutics AB (publ)'s management wants to use your money to grow the business. In return you get a share of Infant Bacterial Therapeutics AB (publ).

First you should know what it really means to hold a share of Infant Bacterial Therapeutics AB (publ). And how you can make/lose money.

Speculation

The Price per Share of Infant Bacterial Therapeutics AB (publ) is kr35.00. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Infant Bacterial Therapeutics AB (publ).
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Infant Bacterial Therapeutics AB (publ), you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr12.64. Based on the TTM, the Book Value Change Per Share is kr-2.50 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.71 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Infant Bacterial Therapeutics AB (publ).

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.25-0.7%-0.25-0.7%-0.23-0.7%-0.16-0.5%-0.12-0.3%
Usd Book Value Change Per Share-0.25-0.7%-0.25-0.7%-0.07-0.2%-0.13-0.4%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.25-0.7%-0.25-0.7%-0.07-0.2%-0.13-0.4%0.030.1%
Usd Price Per Share5.26-6.48-6.49-7.77-9.06-
Price to Earnings Ratio-5.35--6.53--7.06--184.63--116.62-
Price-to-Total Gains Ratio-21.39--26.51--14.90--803.64--539.68-
Price to Book Ratio4.24-3.96-2.81-2.97-4.33-
Price-to-Total Gains Ratio-21.39--26.51--14.90--803.64--539.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.437
Number of shares290
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.25-0.13
Usd Total Gains Per Share-0.25-0.13
Gains per Quarter (290 shares)-71.29-37.83
Gains per Year (290 shares)-285.15-151.32
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-285-2950-151-161
20-570-5800-303-312
30-855-8650-454-463
40-1141-11500-605-614
50-1426-14350-757-765
60-1711-17200-908-916
70-1996-20050-1059-1067
80-2281-22900-1211-1218
90-2566-25750-1362-1369
100-2852-28600-1513-1520

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%3.017.00.015.0%6.032.00.015.8%6.032.00.015.8%
Book Value Change Per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%9.026.03.023.7%9.026.03.023.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.038.00.0%0.00.038.00.0%
Total Gains per Share0.04.00.00.0%2.010.00.016.7%4.016.00.020.0%9.026.03.023.7%9.026.03.023.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Infant Bacterial Therapeutics AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---2.506-2.5030%-0.707-72%-1.328-47%0.333-854%
Book Value Per Share--12.63916.485-23%23.465-46%27.265-54%25.429-50%
Current Ratio--3.3284.850-31%9.576-65%21.550-85%30.502-89%
Debt To Asset Ratio--0.2890.211+37%0.106+172%0.087+234%0.065+344%
Debt To Equity Ratio--0.4070.273+49%0.119+241%0.103+296%0.075+442%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--876153112.0001088070970.000-19%1166684314.550-25%1373893386.410-36%1594072042.616-45%
Eps---2.506-2.541+1%-2.321-7%-1.673-33%-1.186-53%
Ev To Ebitda Ratio---6.527-8.081+24%-9.569+47%81.662-108%-134.500+1961%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.621-2.258+264%-1.910+208%-1.601+158%-1.228+98%
Free Cash Flow To Equity Per Share---0.621-2.221+258%-0.096-85%-1.195+93%0.356-274%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.995+1%
Intrinsic Value_10Y_max---63.334--------
Intrinsic Value_10Y_min---55.394--------
Intrinsic Value_1Y_max---7.562--------
Intrinsic Value_1Y_min---7.428--------
Intrinsic Value_3Y_max---21.794--------
Intrinsic Value_3Y_min---20.825--------
Intrinsic Value_5Y_max---34.909--------
Intrinsic Value_5Y_min---32.482--------
Market Cap455633500.000-58%722068112.000889113720.000-19%877650064.550-18%1039341536.410-31%1205530014.057-40%
Net Profit Margin----1390.7500%-552.7330%-608.0020%-332.3640%
Operating Margin----1390.7000%-552.7560%-611.5080%-338.5510%
Operating Ratio---1489.850-100%598.942-100%644.186-100%351.613-100%
Pb Ratio2.769-53%4.2413.963+7%2.813+51%2.966+43%4.330-2%
Pe Ratio-3.491+35%-5.346-6.533+22%-7.062+32%-184.627+3353%-116.618+2081%
Price Per Share35.000-53%53.60066.000-19%66.100-19%79.115-32%92.224-42%
Price To Free Cash Flow Ratio-14.100+35%-21.593-10.824-50%-8.934-59%-18.616-14%-44.945+108%
Price To Total Gains Ratio-13.964+35%-21.385-26.512+24%-14.900-30%-803.636+3658%-539.676+2424%
Quick Ratio--3.2234.795-33%9.545-66%21.222-85%29.919-89%
Return On Assets---0.141-0.125-11%-0.089-37%-0.065-54%-0.053-63%
Return On Equity---0.198-0.160-19%-0.100-50%-0.075-62%-0.059-70%
Total Gains Per Share---2.506-2.5030%-0.707-72%-1.328-47%0.333-854%
Usd Book Value--16719826.60021807961.400-23%30475535.300-45%35097882.950-52%32636030.916-49%
Usd Book Value Change Per Share---0.246-0.2460%-0.069-72%-0.130-47%0.033-854%
Usd Book Value Per Share--1.2411.619-23%2.304-46%2.677-54%2.497-50%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--86038235.598106848569.254-19%114568399.689-25%134916330.545-36%156537874.585-45%
Usd Eps---0.246-0.249+1%-0.228-7%-0.164-33%-0.117-53%
Usd Free Cash Flow---820952.000-2987612.250+264%-2484926.450+203%-2075565.020+153%-1584878.226+93%
Usd Free Cash Flow Per Share---0.061-0.222+264%-0.188+208%-0.157+158%-0.121+98%
Usd Free Cash Flow To Equity Per Share---0.061-0.218+258%-0.009-85%-0.117+93%0.035-274%
Usd Market Cap44743209.700-58%70907088.59887310967.304-19%86185236.339-18%102063338.875-31%118383047.380-40%
Usd Price Per Share3.437-53%5.2646.481-19%6.491-19%7.769-32%9.056-42%
Usd Profit---3315723.000-3361017.750+1%-3021294.850-9%-2169989.230-35%-1533002.784-54%
Usd Revenue---122.750-100%1890.350-100%446.810-100%1268.847-100%
Usd Total Gains Per Share---0.246-0.2460%-0.069-72%-0.130-47%0.033-854%
 EOD+3 -5MRQTTM+13 -21YOY+7 -275Y+9 -2510Y+9 -26

3.3 Fundamental Score

Let's check the fundamental score of Infant Bacterial Therapeutics AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.491
Price to Book Ratio (EOD)Between0-12.769
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than13.223
Current Ratio (MRQ)Greater than13.328
Debt to Asset Ratio (MRQ)Less than10.289
Debt to Equity Ratio (MRQ)Less than10.407
Return on Equity (MRQ)Greater than0.15-0.198
Return on Assets (MRQ)Greater than0.05-0.141
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Infant Bacterial Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.259
Ma 20Greater thanMa 5038.440
Ma 50Greater thanMa 10042.196
Ma 100Greater thanMa 20042.467
OpenGreater thanClose34.100
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Infant Bacterial Therapeutics AB (publ)

Infant Bacterial Therapeutics AB (publ), a clinical stage pharmaceutical company, develops drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug candidate is IBP-9414, which is in Phase III clinical studies `to prevent necrotizing enterocolitis, as well as to improve feeding tolerance in premature infants. It is also developing IBP-1016 for the treatment of gastroschisis, a rare and severe birth abnormality in infants. In addition, its drug candidates include IBP-1118 to prevent retinopathy of prematurity that causes blindness in premature babies; and IBP-1122, indicated to eliminate vancomycin resistant enterococci that cause antibiotic resistant hospital infections. The company was incorporated in 2011 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2025-03-10 09:12:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Infant Bacterial Therapeutics AB (publ) earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-139,075.0%+139,075.0%
TTM-139,075.0%YOY-55,273.3%-83,801.7%
TTM-139,075.0%5Y-60,800.2%-78,274.8%
5Y-60,800.2%10Y-33,236.4%-27,563.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--98.5%+98.5%
TTM-139,075.0%-193.8%-138,881.2%
YOY-55,273.3%-201.8%-55,071.5%
5Y-60,800.2%-336.9%-60,463.3%
10Y-33,236.4%-483.4%-32,753.0%
4.3.1.2. Return on Assets

Shows how efficient Infant Bacterial Therapeutics AB (publ) is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • -14.1% Return on Assets means that Infant Bacterial Therapeutics AB (publ) generated kr-0.14 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is -14.1%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.1%TTM-12.5%-1.6%
TTM-12.5%YOY-8.9%-3.7%
TTM-12.5%5Y-6.5%-6.1%
5Y-6.5%10Y-5.3%-1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.1%-12.4%-1.7%
TTM-12.5%-12.3%-0.2%
YOY-8.9%-11.8%+2.9%
5Y-6.5%-13.2%+6.7%
10Y-5.3%-15.1%+9.8%
4.3.1.3. Return on Equity

Shows how efficient Infant Bacterial Therapeutics AB (publ) is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • -19.8% Return on Equity means Infant Bacterial Therapeutics AB (publ) generated kr-0.20 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is -19.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -16.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.8%TTM-16.0%-3.9%
TTM-16.0%YOY-10.0%-6.0%
TTM-16.0%5Y-7.5%-8.5%
5Y-7.5%10Y-5.9%-1.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.8%-16.0%-3.8%
TTM-16.0%-16.5%+0.5%
YOY-10.0%-15.2%+5.2%
5Y-7.5%-18.9%+11.4%
10Y-5.9%-20.4%+14.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Infant Bacterial Therapeutics AB (publ).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Infant Bacterial Therapeutics AB (publ) is operating .

  • Measures how much profit Infant Bacterial Therapeutics AB (publ) makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-139,070.0%+139,070.0%
TTM-139,070.0%YOY-55,275.6%-83,794.4%
TTM-139,070.0%5Y-61,150.8%-77,919.2%
5Y-61,150.8%10Y-33,855.1%-27,295.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--204.6%+204.6%
TTM-139,070.0%-292.1%-138,777.9%
YOY-55,275.6%-208.2%-55,067.4%
5Y-61,150.8%-367.9%-60,782.9%
10Y-33,855.1%-480.8%-33,374.3%
4.3.2.2. Operating Ratio

Measures how efficient Infant Bacterial Therapeutics AB (publ) is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM1,489.850-1,489.850
TTM1,489.850YOY598.942+890.908
TTM1,489.8505Y644.186+845.664
5Y644.18610Y351.613+292.573
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.073-2.073
TTM1,489.8503.080+1,486.770
YOY598.9423.231+595.711
5Y644.1864.681+639.505
10Y351.6136.408+345.205
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Infant Bacterial Therapeutics AB (publ).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Infant Bacterial Therapeutics AB (publ) is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 3.33 means the company has kr3.33 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 3.328. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.850. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.328TTM4.850-1.522
TTM4.850YOY9.576-4.727
TTM4.8505Y21.550-16.701
5Y21.55010Y30.502-8.951
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3283.608-0.280
TTM4.8503.860+0.990
YOY9.5764.489+5.087
5Y21.5505.975+15.575
10Y30.5026.291+24.211
4.4.3.2. Quick Ratio

Measures if Infant Bacterial Therapeutics AB (publ) is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A Quick Ratio of 3.22 means the company can pay off kr3.22 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 3.223. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 4.795. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.223TTM4.795-1.572
TTM4.795YOY9.545-4.750
TTM4.7955Y21.222-16.427
5Y21.22210Y29.919-8.697
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2233.013+0.210
TTM4.7953.293+1.502
YOY9.5454.370+5.175
5Y21.2225.939+15.283
10Y29.9196.497+23.422
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Infant Bacterial Therapeutics AB (publ).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Infant Bacterial Therapeutics AB (publ) assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.29 means that Infant Bacterial Therapeutics AB (publ) assets are financed with 28.9% credit (debt) and the remaining percentage (100% - 28.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.289. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.211. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.289TTM0.211+0.078
TTM0.211YOY0.106+0.105
TTM0.2115Y0.087+0.124
5Y0.08710Y0.065+0.021
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2890.340-0.051
TTM0.2110.340-0.129
YOY0.1060.310-0.204
5Y0.0870.363-0.276
10Y0.0650.383-0.318
4.5.4.2. Debt to Equity Ratio

Measures if Infant Bacterial Therapeutics AB (publ) is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A Debt to Equity ratio of 40.7% means that company has kr0.41 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The MRQ is 0.407. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.273. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.407TTM0.273+0.134
TTM0.273YOY0.119+0.153
TTM0.2735Y0.103+0.170
5Y0.10310Y0.075+0.028
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4070.387+0.020
TTM0.2730.426-0.153
YOY0.1190.393-0.274
5Y0.1030.451-0.348
10Y0.0750.495-0.420
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Infant Bacterial Therapeutics AB (publ) generates.

  • Above 15 is considered overpriced but always compare Infant Bacterial Therapeutics AB (publ) to the Biotechnology industry mean.
  • A PE ratio of -5.35 means the investor is paying kr-5.35 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The EOD is -3.491. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.346. Based on the earnings, the company is expensive. -2
  • The TTM is -6.533. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.491MRQ-5.346+1.855
MRQ-5.346TTM-6.533+1.187
TTM-6.533YOY-7.062+0.529
TTM-6.5335Y-184.627+178.093
5Y-184.62710Y-116.618-68.008
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.491-2.056-1.435
MRQ-5.346-2.642-2.704
TTM-6.533-3.222-3.311
YOY-7.062-3.410-3.652
5Y-184.627-6.368-178.259
10Y-116.618-6.851-109.767
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The EOD is -14.100. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -21.593. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.824. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-14.100MRQ-21.593+7.493
MRQ-21.593TTM-10.824-10.769
TTM-10.824YOY-8.934-1.890
TTM-10.8245Y-18.616+7.792
5Y-18.61610Y-44.945+26.329
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.100-2.929-11.171
MRQ-21.593-3.602-17.991
TTM-10.824-3.891-6.933
YOY-8.934-4.295-4.639
5Y-18.616-8.482-10.134
10Y-44.945-9.279-35.666
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Infant Bacterial Therapeutics AB (publ) is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 4.24 means the investor is paying kr4.24 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Infant Bacterial Therapeutics AB (publ):

  • The EOD is 2.769. Based on the equity, the company is underpriced. +1
  • The MRQ is 4.241. Based on the equity, the company is fair priced.
  • The TTM is 3.963. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.769MRQ4.241-1.472
MRQ4.241TTM3.963+0.278
TTM3.963YOY2.813+1.150
TTM3.9635Y2.966+0.997
5Y2.96610Y4.330-1.363
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.7691.880+0.889
MRQ4.2412.163+2.078
TTM3.9632.391+1.572
YOY2.8132.433+0.380
5Y2.9663.843-0.877
10Y4.3304.569-0.239
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets239,566
Total Liabilities69,303
Total Stockholder Equity170,263
 As reported
Total Liabilities 69,303
Total Stockholder Equity+ 170,263
Total Assets = 239,566

Assets

Total Assets239,566
Total Current Assets230,610
Long-term Assets8,956
Total Current Assets
Cash And Cash Equivalents 223,388
Other Current Assets 7,222
Total Current Assets  (as reported)230,610
Total Current Assets  (calculated)230,610
+/-0
Long-term Assets
Intangible Assets 8,886
Long-term Assets Other 70
Long-term Assets  (as reported)8,956
Long-term Assets  (calculated)8,956
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities69,303
Long-term Liabilities0
Total Stockholder Equity170,263
Total Current Liabilities
Accounts payable 46,993
Other Current Liabilities 22,310
Total Current Liabilities  (as reported)69,303
Total Current Liabilities  (calculated)69,303
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock3,672
Retained Earnings -602,251
Other Stockholders Equity 768,842
Total Stockholder Equity (as reported)170,263
Total Stockholder Equity (calculated)170,263
+/-0
Other
Capital Stock3,672
Cash and Short Term Investments 223,388
Common Stock Shares Outstanding 13,471
Liabilities and Stockholders Equity 239,566
Net Debt -223,388
Net Invested Capital 170,263
Net Working Capital 161,307



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-31
> Total Assets 
0
0
82,543
82,543
0
133,127
0
110,109
100,925
92,224
83,006
175,024
597,313
600,420
589,820
563,371
561,035
554,977
545,348
518,273
523,168
492,620
480,304
450,318
451,138
429,414
421,452
408,478
409,967
400,007
396,361
349,619
333,694
317,390
386,715
351,334
348,878
296,444
239,303
239,566
239,566239,303296,444348,878351,334386,715317,390333,694349,619396,361400,007409,967408,478421,452429,414451,138450,318480,304492,620523,168518,273545,348554,977561,035563,371589,820600,420597,313175,02483,00692,224100,925110,1090133,127082,54382,54300
   > Total Current Assets 
1,054
0
66,318
66,318
44,411
116,902
0
94,695
85,715
77,168
68,154
160,376
582,869
586,180
575,784
549,539
547,407
541,553
532,128
505,257
510,356
480,012
467,900
438,118
439,142
417,622
409,864
397,094
398,767
389,011
385,569
339,031
323,310
307,210
376,739
341,562
339,310
287,080
230,143
230,610
230,610230,143287,080339,310341,562376,739307,210323,310339,031385,569389,011398,767397,094409,864417,622439,142438,118467,900480,012510,356505,257532,128541,553547,407549,539575,784586,180582,869160,37668,15477,16885,71594,6950116,90244,41166,31866,31801,054
       Cash And Cash Equivalents 
-1,054
0
44,411
44,411
-44,411
116,384
0
93,786
84,673
76,323
67,176
158,274
581,081
576,800
566,786
542,170
540,514
539,453
511,888
495,188
500,995
473,608
463,043
423,438
425,758
409,066
390,360
386,752
382,179
373,976
368,331
335,840
306,680
300,953
367,207
329,064
309,618
272,510
226,196
223,388
223,388226,196272,510309,618329,064367,207300,953306,680335,840368,331373,976382,179386,752390,360409,066425,758423,438463,043473,608500,995495,188511,888539,453540,514542,170566,786576,800581,081158,27467,17676,32384,67393,7860116,384-44,41144,41144,4110-1,054
       Short-term Investments 
2,109
0
0
0
88,822
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000088,8220002,109
       Net Receivables 
0
0
0
0
0
0
0
53
49
0
0
0
0
0
0
0
0
0
665
713
1,587
910
1,627
1,955
77
8,556
2,857
10,342
1,134
15,035
17,239
1,778
16,630
6,257
9,532
6,736
29,692
14,570
0
0
0014,57029,6926,7369,5326,25716,6301,77817,23915,0351,13410,3422,8578,556771,9551,6279101,58771366500000000049530000000
       Other Current Assets 
0
0
21,907
21,907
0
518
0
856
993
845
978
2,102
1,788
9,380
8,998
7,369
6,893
2,100
20,240
10,069
9,361
6,404
4,857
14,680
13,307
8,556
19,504
10,342
16,588
15,035
17,238
3,191
16,630
6,257
9,532
5,762
29,692
14,570
3,947
7,222
7,2223,94714,57029,6925,7629,5326,25716,6303,19117,23815,03516,58810,34219,5048,55613,30714,6804,8576,4049,36110,06920,2402,1006,8937,3698,9989,3801,7882,1029788459938560518021,90721,90700
   > Long-term Assets 
-1,054
0
16,225
16,225
-44,411
16,225
0
15,414
15,210
15,056
14,852
14,648
14,444
14,240
14,036
13,832
13,628
13,424
13,220
13,016
12,812
12,608
12,404
12,200
11,996
11,792
11,588
11,384
11,200
10,996
10,792
10,588
10,384
10,180
9,976
9,772
9,568
9,364
9,160
8,956
8,9569,1609,3649,5689,7729,97610,18010,38410,58810,79210,99611,20011,38411,58811,79211,99612,20012,40412,60812,81213,01613,22013,42413,62813,83214,03614,24014,44414,64814,85215,05615,21015,414016,225-44,41116,22516,2250-1,054
       Intangible Assets 
0
0
0
0
0
0
0
15,414
0
15,006
14,802
14,598
14,394
14,190
13,986
13,782
13,578
13,374
13,170
12,966
12,762
12,558
12,354
12,150
11,946
11,742
11,538
11,334
11,130
10,926
10,722
10,518
10,314
10,110
9,906
9,702
9,498
9,294
9,090
8,886
8,8869,0909,2949,4989,7029,90610,11010,31410,51810,72210,92611,13011,33411,53811,74211,94612,15012,35412,55812,76212,96613,17013,37413,57813,78213,98614,19014,39414,59814,80215,006015,4140000000
       Long-term Assets Other 
-1,054
0
16,225
16,225
-44,411
16,225
0
0
15,210
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
50
70
70
70
70
70
70
70
0
70
70
70
70
707070700707070707070705050505050505050505050505050505050505015,2100016,225-44,41116,22516,2250-1,054
> Total Liabilities 
0
0
7,734
7,734
0
6,079
0
4,883
4,262
8,625
3,993
6,653
8,161
10,603
8,960
6,654
5,005
6,507
7,417
7,876
11,593
8,965
15,249
10,164
10,446
17,886
9,980
13,224
33,914
20,402
24,539
17,913
24,456
36,462
40,669
46,180
71,538
59,767
35,275
69,303
69,30335,27559,76771,53846,18040,66936,46224,45617,91324,53920,40233,91413,2249,98017,88610,44610,16415,2498,96511,5937,8767,4176,5075,0056,6548,96010,6038,1616,6533,9938,6254,2624,88306,07907,7347,73400
   > Total Current Liabilities 
0
0
7,734
7,734
0
6,079
0
4,883
4,262
8,625
3,993
6,653
8,161
10,603
8,960
6,654
5,005
6,507
7,417
7,876
11,593
8,965
15,249
10,164
10,446
17,886
9,980
13,224
33,914
20,402
24,540
17,913
24,457
36,462
40,669
46,180
71,539
59,766
35,276
69,303
69,30335,27659,76671,53946,18040,66936,46224,45717,91324,54020,40233,91413,2249,98017,88610,44610,16415,2498,96511,5937,8767,4176,5075,0056,6548,96010,6038,1616,6533,9938,6254,2624,88306,07907,7347,73400
       Accounts payable 
0
0
518
518
0
269
0
1,116
1,915
1,150
668
506
1,326
1,083
5,543
3,507
910
2,432
2,809
943
1,385
208
7,339
1,232
3,400
5,985
5,180
4,797
19,843
6,535
6,449
8,746
7,145
18,324
25,543
30,067
41,364
45,120
12,097
46,993
46,99312,09745,12041,36430,06725,54318,3247,1458,7466,4496,53519,8434,7975,1805,9853,4001,2327,3392081,3859432,8092,4329103,5075,5431,0831,3265066681,1501,9151,1160269051851800
       Other Current Liabilities 
0
0
7,216
7,216
0
5,810
0
3,767
2,347
7,475
3,325
6,147
6,835
9,520
3,417
3,147
4,095
4,075
4,608
6,933
10,208
8,757
7,910
8,932
7,046
11,901
4,800
8,427
14,071
13,867
18,091
9,167
17,312
18,138
15,126
16,113
30,175
14,646
23,179
22,310
22,31023,17914,64630,17516,11315,12618,13817,3129,16718,09113,86714,0718,4274,80011,9017,0468,9327,9108,75710,2086,9334,6084,0754,0953,1473,4179,5206,8356,1473,3257,4752,3473,76705,81007,2167,21600
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,797
19,843
6,535
-1
8,746
-1
0
0
1
-1
1
-1
0
0-11-1100-18,746-16,53519,8434,797000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
-1
0
0
0
0
0
0
000000-1010000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,578
0
13,170
12,966
12,762
12,558
12,354
12,150
11,946
11,742
11,538
11,334
11,130
10,926
10,722
10,518
0
10,110
0
0
0
0
0
0
00000010,110010,51810,72210,92611,13011,33411,53811,74211,94612,15012,35412,55812,76212,96613,170013,5780000000000000000
> Total Stockholder Equity
11,031
0
74,809
74,809
74,809
127,048
0
105,226
96,663
83,599
79,013
168,371
589,152
589,817
580,860
556,717
556,030
548,470
537,931
510,397
511,575
483,655
465,055
440,154
440,692
411,528
411,472
395,254
376,053
379,605
371,822
331,706
309,238
280,928
346,046
305,154
277,340
236,677
204,028
170,263
170,263204,028236,677277,340305,154346,046280,928309,238331,706371,822379,605376,053395,254411,472411,528440,692440,154465,055483,655511,575510,397537,931548,470556,030556,717580,860589,817589,152168,37179,01383,59996,663105,2260127,04874,80974,80974,809011,031
   Common Stock
0
0
500
500
0
1,500
0
1,500
1,500
1,500
1,500
1,800
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,060
3,672
3,672
3,672
3,672
3,672
3,672
3,6723,6723,6723,6723,6723,6723,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0603,0601,8001,5001,5001,5001,50001,500050050000
   Retained Earnings Total Equity0000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
11,031
0
0
0
74,809
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
672,078
0
0
0
0
0
-1
-1
0
0
0
1
-1
-2
0
0
00-2-11000-1-100000672,078000000000000000000074,80900011,031
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
667,167
667,167
667,184
667,184
668,931
669,018
669,019
669,022
669,022
669,022
670,926
670,926
670,926
670,926
671,436
0
0
0
0
0
0
000000671,436670,926670,926670,926670,926669,022669,022669,022669,019669,018668,931667,184667,184667,167667,1670000000000000000000
   Treasury Stock0000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
52,350
52,350
0
140,473
0
140,473
140,473
141,357
141,357
239,474
668,139
668,139
667,167
667,167
667,167
667,167
667,167
667,167
667,167
667,184
667,184
668,931
669,018
669,019
669,022
669,022
669,022
670,926
670,924
670,925
670,926
671,436
766,829
766,828
766,827
768,838
768,842
768,842
768,842768,842768,838766,827766,828766,829671,436670,926670,925670,924670,926669,022669,022669,022669,019669,018668,931667,184667,184667,167667,167667,167667,167667,167667,167667,167668,139668,139239,474141,357141,357140,473140,4730140,473052,35052,35000



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-0
Gross Profit00
 
Operating Income (+$)
Gross Profit0
Operating Expense-145,343
Operating Income-145,343-145,343
 
Operating Expense (+$)
Research Development126,051
Selling General Administrative19,296
Selling And Marketing Expenses0
Operating Expense145,343145,347
 
Net Interest Income (+$)
Interest Income8,438
Interest Expense-0
Other Finance Cost-0
Net Interest Income8,438
 
Pretax Income (+$)
Operating Income-145,343
Net Interest Income8,438
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-136,905-145,343
EBIT - interestExpense = 0
-136,905
-136,905
Interest Expense0
Earnings Before Interest and Taxes (EBIT)0-136,905
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-136,905
Tax Provision-0
Net Income From Continuing Ops-136,905-136,905
Net Income-136,905
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-8,438
 

Technical Analysis of Infant Bacterial Therapeutics AB (publ)
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Infant Bacterial Therapeutics AB (publ). The general trend of Infant Bacterial Therapeutics AB (publ) is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Infant Bacterial Therapeutics AB (publ)'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Infant Bacterial Therapeutics AB (publ).

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 38.40 < 38.40 < 42.20.

The bearish price targets are: 34.00 > 34.00 > 34.00.

Tweet this
Infant Bacterial Therapeutics AB (publ) Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Infant Bacterial Therapeutics AB (publ). The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Infant Bacterial Therapeutics AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Infant Bacterial Therapeutics AB (publ). The current macd is -1.92365834.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Infant Bacterial Therapeutics AB (publ) price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Infant Bacterial Therapeutics AB (publ). This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Infant Bacterial Therapeutics AB (publ) price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Infant Bacterial Therapeutics AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartInfant Bacterial Therapeutics AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Infant Bacterial Therapeutics AB (publ). The current adx is 13.48.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Infant Bacterial Therapeutics AB (publ) shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Infant Bacterial Therapeutics AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Infant Bacterial Therapeutics AB (publ). The current sar is 39.15.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Infant Bacterial Therapeutics AB (publ) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Infant Bacterial Therapeutics AB (publ). The current rsi is 36.26. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Infant Bacterial Therapeutics AB (publ) Daily Relative Strength Index (RSI) ChartInfant Bacterial Therapeutics AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Infant Bacterial Therapeutics AB (publ). The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Infant Bacterial Therapeutics AB (publ) price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Infant Bacterial Therapeutics AB (publ) Daily Stochastic Oscillator ChartInfant Bacterial Therapeutics AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Infant Bacterial Therapeutics AB (publ). The current cci is -136.87368737.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Infant Bacterial Therapeutics AB (publ) Daily Commodity Channel Index (CCI) ChartInfant Bacterial Therapeutics AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Infant Bacterial Therapeutics AB (publ). The current cmo is -30.48709025.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Infant Bacterial Therapeutics AB (publ) Daily Chande Momentum Oscillator (CMO) ChartInfant Bacterial Therapeutics AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Infant Bacterial Therapeutics AB (publ). The current willr is -83.72093023.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Infant Bacterial Therapeutics AB (publ) Daily Williams %R ChartInfant Bacterial Therapeutics AB (publ) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Infant Bacterial Therapeutics AB (publ).

Infant Bacterial Therapeutics AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Infant Bacterial Therapeutics AB (publ). The current atr is 2.29033672.

Infant Bacterial Therapeutics AB (publ) Daily Average True Range (ATR) ChartInfant Bacterial Therapeutics AB (publ) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Infant Bacterial Therapeutics AB (publ). The current obv is -240,339.

Infant Bacterial Therapeutics AB (publ) Daily On-Balance Volume (OBV) ChartInfant Bacterial Therapeutics AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Infant Bacterial Therapeutics AB (publ). The current mfi is 29.41.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Infant Bacterial Therapeutics AB (publ) Daily Money Flow Index (MFI) ChartInfant Bacterial Therapeutics AB (publ) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Infant Bacterial Therapeutics AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-10-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-10-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-29WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-31STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-01MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-06CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-26WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-06STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-10RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-17MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-18MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-19MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-09WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-14BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-17MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-01-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-03STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-05SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-17STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-04STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-10STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-13STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Infant Bacterial Therapeutics AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Infant Bacterial Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5036.259
Ma 20Greater thanMa 5038.440
Ma 50Greater thanMa 10042.196
Ma 100Greater thanMa 20042.467
OpenGreater thanClose34.100
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Infant Bacterial Therapeutics AB (publ) with someone you think should read this too:
  • Are you bullish or bearish on Infant Bacterial Therapeutics AB (publ)? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Infant Bacterial Therapeutics AB (publ)? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Infant Bacterial Therapeutics AB (publ)

I send you an email if I find something interesting about Infant Bacterial Therapeutics AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Infant Bacterial Therapeutics AB (publ).

Receive notifications about Infant Bacterial Therapeutics AB (publ) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.